Our findings extend these clinical observations by proposing a gene-guided application: Dexamethasone may be particularly beneficial in MetS patients with upregulated Traf1/Kcnmb1 expression, suggesting a precision medicine approach for patient stratification. The gene discussed is TRAF1; the disease is metabolic syndrome.